China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...

after a small phase 3 trial in yet another skin disorder – chronic pruritus of unknown origin (CPUO) – failed to show a statistically significant benefit with Dupixent on the primary itch ...

AbbVie Humira, Pfizer/BioNTech COVID-19 shot may not make top 10 pharma drugs in 2024, with Novo Nordisk Ozempic and ...

A substantial number of patients with brain metastases who experience cognitive side effects following radiation therapy may ...